Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab <i>versus</i> bevacizumab alone in women with newly diagnosed advanced ovarian cancer.

导出 OA

翻译打印收藏纠错

作者： Robert,Hettle ^[1] ; Charles,McCrea ^[2] ; Chee Khoon,Lee ^[3] ; Richard,Davidson ^[4]

作者单位： Health Economics and Payer Evidence, AstraZeneca, Academy House, 136 Hills Road, Cambridge, Cambridgeshire CB2 8PA, UK. ^[1] Health Economics and Payer Evidence, AstraZeneca, Cambridge, UK. ^[2] Cancer Care Centre, St George Hospital, Sydney, Australia. ^[3] Global Medical Affairs, AstraZeneca, Cambridge, UK. ^[4]

关键词 bevacizumab homologous recombination deficiency indirect treatment comparison niraparib olaparib ovarian cancer

DOI 10.1177/17588359211049639

PMID 34616492

发布时间 2024-04-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Therapeutic advances in medical oncology

2021年13卷

17588359211049639页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab <i>versus</i> bevacizumab alone in women with newly diagnosed advanced ovarian cancer.

Therapeutic advances in medical oncology

相似文献

Therapeutic advances in medical oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab <i>versus</i> bevacizumab alone in women with newly diagnosed advanced ovarian cancer.

Therapeutic advances in medical oncology

相似文献

Therapeutic advances in medical oncology

相关期刊

检索历史清除